Table 1.
Cancer types/cell type | MicroRNAs | Target genes | Immunological component/process | References |
---|---|---|---|---|
Hepatocellular Carcinoma |
miR-34a | DAPK2/SP1 pathway | Dendritic cell activation | [74] |
miR-34a | PD-L1 | PD-1/PD-L1 immune checkpoint blockade | [75] | |
miR-146a | Effector of STAT3 | NK cells and anti-tumor lymphocytes | [76] | |
miR-20a, miR-93 and miR-106b | MICA/B | Antigen presentation and immune evasion | [79] | |
miR-101 | DUSP1 | Proinflammatory factors and tumor-associated macrophages | [82] | |
miR-26a | Macrophage colony-stimulating factor (M-CSF) | Chemokine ligand (CCL) 22, IL10 and macrophage infiltration | [84] | |
miR-122 | HCV genome | Assisting replication of HCV | [86] | |
miR-122 | Cyclin G1 | Inhibiting transcription of HBV | [88] | |
miR-122 | Suppressor of cytokine signaling 3 (SOCS3) | Interferon production | [89] | |
miR-122 | Chemokine (C-C motif) ligand 2 (CCL2) | CCR2+CD11bhighGr1+ immune cells recruitment, proinflammatory cytokine production | [90] | |
miR-185 | LDLR, SCD1, SCARB1 and SREBP2 | HCV replication | [91] | |
miR-130b | LDLR, lipid metabolism pathway | HCV replication; reinforcing the antiviral activity of 25-hydroxycholesterol (25-HC), | [91] | |
| ||||
Pancreatic Cancer |
miR-203 | Toll-Like Receptor 4 | Modulating TLR-mediated immune response and facilitate immune escape | [92] |
miR-142-5p | PD-L1 | PD-1/PD-L1 immune checkpoint blockade | [93] | |
miR-454 | Stromal cell derived factor-1 | Macrophage recruitment and dendritic cell maturation | [94] | |
miR-206 | Chemokines (C-X-C motif) ligand 1 and (C-C motif) ligand 2, Interleukin-8 and the granulocyte macrophage colony-stimulating factor | Inhibiting inflammation and immune reaction | [95] | |
miR-206 | Vascular endothelial growth factor C | Inhibiting blood and lymphatic vessel formation | [95] | |
miR-9 | unknown | Inflammation of acute pancreatitis | [96] | |
miR-216a | PTEN, Smad7, pAkt and TGF-β receptor 1 | Inflammation of acute pancreatitis | [97] | |
miR-146a | IL-1b, IL-6 and TNF-a | Inflammation of chronic pancreatitis | [98] | |
| ||||
Colorectal Cancer |
miR-222 and -339 | ICAM-1 | Promotes cytotoxicity of CTL's | [99] |
miR-21 | PDCD4 | IL-10 transcription and CD3+ and CD45RO+ cell selection | [100] | |
miR-17-5p and -20a | STAT3 | Decreased burden from reactive oxygen species and inhibition of MDSC immunosuppression | [101, 102] | |
miR-124 | STAT3 | Decreased progression of ulcerative colitis | [103] | |
miR-19b | HIF-alpha | Anti-inflammatory in Crohn's disease | [104] | |
miR-494 | PTEN | Increased number of pro-cancer MDSC's | ||
miR-484 and -19a | CD137L | Decreased PI3K/mTOR signaling and IL-8 production | [105] | |
miR-142-5p | PD-L1 | Increased viability of CTL's | [93] | |
miR-20b, -21, and -130b | PTEN | PD-L1 overexpression and CRC proliferation | [101, 106] | |
| ||||
Gastric Cancer | miR-34a | DAPK2/SP1 | Increased dendritic cell immune response | [74] |
| ||||
Gallbladder Cancer |
miR-218-5p | Downregulated by lncRNA CCAT1 | Modulation of the tumor micro-environment | [107] |
miR-155 | IFNγ | Activation and proliferation of CD4+ and CD8+ T cells | [108] | |
miR-133a-3p | Recombination signal-binding protein Jκ | Differentiation of T cell lineage from common lymphoid precursor. | [109] | |
miR-1, miR-133, miR-143 and miR-145 | VEGF-A, ErbB3, AXL | Modulation of the tumor micro-environment | [110] | |
| ||||
Esophageal Cancer | miR-31 | STK40 | Inflammatory signaling | [111] |
miR-34a | Upregulated by NF-kappaB | Inflammation signaling | [112] | |
miR-155 | SOCS1/JAK/STAT pathway | Normal function of Kupffer cells | [113] | |
miR-21 | Exosomal miRNA | T cells and macrophages activation | [114] |